| 2.5875 -0.053 (-1.99%) | 12-05 10:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.21 | 1-year : | 3.75 |
| Resists | First : | 2.75 | Second : | 3.21 |
| Pivot price | 2.47  |
|||
| Supports | First : | 2.07 | Second : | 1.64 |
| MAs | MA(5) : | 2.63  |
MA(20) : | 2.32 |
| MA(100) : | 1.9 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 85.3 |
D(3) : | 87.5 |
| RSI | RSI(14): 67.8 |
|||
| 52-week | High : | 2.75 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MIST ] has closed below upper band by 33.7%. Bollinger Bands are 51.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.66 - 2.68 | 2.68 - 2.69 |
| Low: | 2.54 - 2.56 | 2.56 - 2.57 |
| Close: | 2.61 - 2.64 | 2.64 - 2.67 |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Tue, 02 Dec 2025
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Tue, 02 Dec 2025
Milestone Pharmaceuticals (Nasdaq: MIST) issues 30,000 options at $2.69 under 2021 Inducement Plan - Stock Titan
Tue, 02 Dec 2025
Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Tue, 25 Nov 2025
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Yahoo Finance
Tue, 18 Nov 2025
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate - Yahoo Finance
Sat, 15 Nov 2025
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 85 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 46.2 (%) |
| Shares Short | 4,950 (K) |
| Shares Short P.Month | 5,170 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42 % |
| Return on Equity (ttm) | -260.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -3.29 |
| PEG Ratio | 0 |
| Price to Book value | 12.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|